CN1698628A - 一种美容修护液及其制备方法 - Google Patents
一种美容修护液及其制备方法 Download PDFInfo
- Publication number
- CN1698628A CN1698628A CN 200410009110 CN200410009110A CN1698628A CN 1698628 A CN1698628 A CN 1698628A CN 200410009110 CN200410009110 CN 200410009110 CN 200410009110 A CN200410009110 A CN 200410009110A CN 1698628 A CN1698628 A CN 1698628A
- Authority
- CN
- China
- Prior art keywords
- maintenance liquid
- preparation
- acyclovir
- metronidazole
- dexamethasone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 16
- 238000012423 maintenance Methods 0.000 title claims abstract description 15
- 230000003796 beauty Effects 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title claims description 6
- 239000003814 drug Substances 0.000 claims abstract description 11
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims abstract description 8
- 229930182566 Gentamicin Natural products 0.000 claims abstract description 8
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960004150 aciclovir Drugs 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 229960000282 metronidazole Drugs 0.000 claims abstract description 8
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims abstract description 8
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims abstract description 6
- 229960003957 dexamethasone Drugs 0.000 claims abstract description 6
- 238000003756 stirring Methods 0.000 claims abstract description 3
- 239000012467 final product Substances 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 230000035876 healing Effects 0.000 abstract description 6
- 231100000241 scar Toxicity 0.000 abstract description 4
- 208000032544 Cicatrix Diseases 0.000 abstract 1
- 206010039509 Scab Diseases 0.000 abstract 1
- 238000004061 bleaching Methods 0.000 abstract 1
- 230000005587 bubbling Effects 0.000 abstract 1
- 229960002518 gentamicin Drugs 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000037387 scars Effects 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
- 208000003251 Pruritus Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229940097957 dexamethasone 2 mg Drugs 0.000 description 1
- 229940084973 dexamethasone 4 mg Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种美容修护液，由下列药品制成：阿昔洛韦、地塞米松、庆大霉素、甲硝唑。将上述药物混合在一起，搅拌均匀即可。漂唇后敷用该修护液，即可起到防止起泡、感染、结痂、伤口难以愈合或者愈合后留下永久性疤痕的作用。还适用于漂唇后的排异反应。成本低廉，效果显著。
Description
技术领域
本发明涉及一种美容用品，特别是涉及一种美容修护液及其制备方法。
技术背景
随着美容日益普遍，其副作用也日益受到重视。一个长期困扰美容界的问题是漂唇后唇部容易起泡、感染、结痂、伤口难以愈合或者愈合后留下永久性疤痕，造成美容不成反而毁容的后果，特别是当使用的漂唇色素质量不合格时上述症状更加严重。
但是，到目前为止，还没有一种有效的药物可以解决上述问题。
发明内容
本发明的目的提供一种美容修护液及其制备方法，彻底解决漂唇的后遗症。
本发明采用如下技术方案来实现发明目的。
本发明美容修护液由下述配比的四种药物制成：
阿昔洛韦0.2-0.6g 地塞米松2-4mg
庆大霉素8-16万单位 甲硝唑10-50ml
上述四种药物都可以从市面上购得。
配方中各组分的适应症分别是：
阿昔洛韦：1)单纯疱疹病毒感染；2)带状疱疹，适用于免疫功能正常者带状疱疹和免疫缺陷者轻型病例的治疗
地塞米松：用于过敏性与自身免疫性炎症疾病，多用于结缔组织病、活动性风湿病、类风湿性关节炎、红斑狼疮、严重支气管哮喘、严重皮炎、溃疡性结肠炎、急性白血病，也用于某些严重感染及中毒、恶性淋巴瘤的综合治疗。
庆大霉素：败血症、下呼吸道感染、腹腔感染、皮肤软组织感染、复杂性尿路感染。
甲硝唑：主要用于厌氧菌感染的治疗
将上述四种药品按照配方称量后混合在一起，搅拌均匀即可。
本发明美容修护液的功效：消炎、抗过敏、去腐生肌、去疱疹。
使用方法：漂唇后每天用本发明美容修护液敷2-3次，视具体情况连续使用3-5天，即可起到防止起泡、感染、结痂、伤口难以愈合或者愈合后留下永久性疤痕的作用。
本发明美容修护液还适用于漂唇后的排异反应，即涂有色素的部位凸出皮肤表面，发红、发痒、发干，裂口。具体用法是用消毒后的针将凸出皮肤表面部位刺破，将本发明美容修护液敷2-3次。1-3天即可见效，视具体情况连续使用5-12天，上述症状即可完全消除。
本发明美容修护液成本低廉，制备简单，使用方便，效果显著。
具体实施方式
下面通过具体实施例来进一步说明本发明。
【实施例1】
由下述配比的四种药物制成：阿昔洛韦0.2g(2片)、地塞米松2mg(2支)、庆大霉素8万单位、甲硝唑50ml
【实施例2】
由下述配比的四种药物制成：阿昔洛韦0.4g(4片)、地塞米松3mg(3支)、庆大霉素12万单位、甲硝唑30ml
【实施例3】
由下述配比的四种药物制成：阿昔洛韦0.6g(6片)、地塞米松4mg(4支)、庆大霉素16万单位、甲硝唑10ml
实施例1制得的本发明美容修护液经过对589例漂唇者临床使用，对漂唇后预防起泡、感染、结痂、伤口难以愈合或者愈合后留下永久性疤痕有效率达到100％，没有留下任何不良后果。
实施例1制得的本发明美容修护液对漂唇后的排异反应治疗效果如下：
| 症 状 | 病例数 | 见效时间 | 治愈时间 | 有效率 |
| 突出皮肤、发红 | 132 | 1.3天 | 5.9天 | 100％ |
| 发红、发痒 | 354 | 1.2天 | 6.4天 | 100％ |
| 发干 | 56 | 1.1天 | 4.5天 | 100％ |
| 发干、裂口 | 86 | 2.5天 | 11.2天 | 100％ |
| 突出皮肤、发痒 | 83 | 1.8天 | 8.7天 | 100％ |
| 突出皮肤、发痒、裂口 | 15 | 3.1天 | 10.8天 | 100％ |
Claims (2)
1、一种美容修护液，由下述配比的四种药物制成：
阿昔洛韦0.2-0.6g 地塞米松2-4mg
庆大霉素8-16万单位 甲硝唑10-50ml。
2、一种美容修护液的制备方法，包括如下步骤：
(1)按照下述配比称量药物：
阿昔洛韦0.2-0.6g 地塞米松2-4mg
庆大霉素8-16万单位 甲硝唑10-50ml
(2)将上述药物混合在一起，搅拌均匀即可。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100091100A CN1293883C (zh) | 2004-05-21 | 2004-05-21 | 一种美容修护液及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100091100A CN1293883C (zh) | 2004-05-21 | 2004-05-21 | 一种美容修护液及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1698628A true CN1698628A (zh) | 2005-11-23 |
| CN1293883C CN1293883C (zh) | 2007-01-10 |
Family
ID=35474979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100091100A Expired - Fee Related CN1293883C (zh) | 2004-05-21 | 2004-05-21 | 一种美容修护液及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1293883C (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105073121A (zh) * | 2012-12-27 | 2015-11-18 | 帕西法尔·维嘉·比亚维森西奥 | 半透性多孔人造痂的形成 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6093414A (en) * | 1997-08-11 | 2000-07-25 | Christopher C. Capelli | Silver-based antimicrobial compositions |
| US6197776B1 (en) * | 1999-03-17 | 2001-03-06 | Ernest L. Bonner, Jr. | Method for treatment of reactive arthritis or bursitis |
| US6765000B2 (en) * | 1999-03-17 | 2004-07-20 | Bonner Jr Ernest L | Treatment for reactive arthritis or bursitis |
| IT1317735B1 (it) * | 2000-01-26 | 2003-07-15 | Nicox Sa | Sali di agenti antimicrobici. |
-
2004
- 2004-05-21 CN CNB2004100091100A patent/CN1293883C/zh not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105073121A (zh) * | 2012-12-27 | 2015-11-18 | 帕西法尔·维嘉·比亚维森西奥 | 半透性多孔人造痂的形成 |
| CN105073121B (zh) * | 2012-12-27 | 2018-12-04 | 帕西法尔·维嘉·比亚维森西奥 | 半透性多孔人造痂的形成 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1293883C (zh) | 2007-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Asthana et al. | Polyvinyl alcohol (PVA) mixed green–clay and aloe vera based polymeric membrane optimization: Peel-off mask formulation for skin care cosmeceuticals in green nanotechnology | |
| EP2869854B1 (de) | Zusammensetzung, enthaltend als wirkstoff ectoin oder hydroxyectoin zur förderung der wiederherstellung von verletztem körpergewebe | |
| Deng et al. | Diabetes immunity-modulated multifunctional hydrogel with cascade enzyme catalytic activity for bacterial wound treatment | |
| CN103304107B (zh) | 一种处理柑橘罐头果胶废水的方法 | |
| EP2745849B1 (en) | Polydeoxyribonucleotides composition and uses thereof | |
| CN102793785B (zh) | 一种三黄止痒搽剂及其制备方法 | |
| EP0299369B1 (de) | Dezentrales Klärverfahren | |
| CN1293883C (zh) | 一种美容修护液及其制备方法 | |
| CN103159357A (zh) | 一种消除水体中抗生素抗性基因污染的方法 | |
| CN105943520B (zh) | 一种生物响应性靶向双药物缓释载体材料及其制备方法 | |
| DE2640875A1 (de) | Zweistufiges belebtschlammverfahren | |
| CN102126780B (zh) | 一种高效cod去除剂在废水处理中的应用 | |
| KR100907357B1 (ko) | 반사방지 코팅용 코팅제, 제조방법 및 반사방지필름 | |
| CN103058455B (zh) | 一种利用活性焦处理印染废水的系统及其工艺 | |
| CN104591378A (zh) | 一种生化污泥膨胀控制系统及其控制方法 | |
| CN202865068U (zh) | 生物制药业废水处理系统 | |
| CN1272019C (zh) | 医用复合甲壳胺凝胶液 | |
| CN113213703A (zh) | 一种制药废水处理系统及工艺 | |
| CN1247204C (zh) | 治疗脚气的药物 | |
| CN106497382B (zh) | 一种用于饮用水领域的抑菌涂料、抑菌水箱及制备方法 | |
| DE60016581T2 (de) | Funktionalisiertes polymer von glykosaminoglycan, arzneimittel und medizinische instrumente zu seiner herstellung | |
| CN113637301A (zh) | 一种可降解微生物营养缓释微球及其制备方法和应用 | |
| CN1965841A (zh) | 一种复方丁酸氢化可的松乳膏 | |
| CN100453121C (zh) | 一种医用敷料及其生产方法 | |
| DE3732370A1 (de) | Verfahren zur vermischung von lebenden zellen oder mikroorganismen mit einer viskosen fluessigkeit und mischungen, die nach diesem verfahren hergestellt wurden |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070110 Termination date: 20160521 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |